亦诺微押注前沿疗法冲刺港股。1月14日，亦诺微正式向港交所递交招股书，寻求上市突围。财务数据 显示，亦诺微成立十年至今，仍无产品进入商业化阶段，2023年至2025年前9个月，其总营收仅维持在 千万元级别，受持续的研发投入及可转换可赎回优先股公允价值变动影响，截至2025年9月底，亦诺微 累计亏损已超过23亿元。 值得关注的是，为扫清上市障碍，亦诺微在首次递表之际对优先股赎回条款进行了关键调整，递表后赎 回权自动失效。这虽缓解了眼前的财务压力，但公司面临的研发与市场挑战依然严峻。亦诺微核心产品 MVR-T3011目前仍处于II期临床试验阶段，然而，全球溶瘤免疫疗法赛道竞争已异常激烈，加之该领域 2024年全球市场规模仅约8710万美元，市场空间有限。在重重压力之下，此次赴港IPO能否成为亦诺微 扭转局面的关键一步，仍是未知数。 核心产品市场规模有限 据了解，亦诺微成立于2015年，主要布局新型溶瘤免疫疗法和工程化外泌体疗法。目前，该公司的产品 管线包括2款针对实体瘤的溶瘤免疫疗法产品、两款临床前阶段工程化外泌体治疗产品以及3款可直接商 业化的工程化外泌体产品。 其中，核心产品MVR-T3011是一款处于II期 ...

Core Viewpoint - Yinuo Micro is seeking to go public in Hong Kong to overcome financial challenges, despite having no commercialized products and facing significant losses and competition in the oncolytic immunotherapy market [1][8]. Financial Performance - Yinuo Micro has reported total revenues of RMB 6.772 million, RMB 3.2 million, and RMB 1.305 million for the years ending December 31, 2023, and September 30, 2024, respectively [2]. - The company has incurred substantial losses, with pre-tax losses of RMB 481.753 million, RMB 523.755 million, and RMB 337.910 million for the same periods [2][3]. - Cumulative losses have exceeded RMB 2.371 billion as of September 30, 2025, with a net current liability of RMB 2.19 billion and cash reserves of only RMB 68.594 million [3][4]. IPO Strategy - To facilitate the IPO process, Yinuo Micro has adjusted the redemption rights of its preferred shares, which will automatically become void upon the submission of the IPO application [5]. - The company has completed seven rounds of financing, raising over RMB 1 billion, but still faces pressure to complete the IPO to ensure operational continuity [4][8]. Product Pipeline and Market Challenges - Yinuo Micro's core product, MVR-T3011, is currently in Phase II clinical trials, targeting various solid tumors [6]. - The global market for oncolytic immunotherapy is projected to be only USD 8.71 million in 2024, indicating limited market potential [7]. - The company faces intense competition, with 18 oncolytic immunotherapy drugs in clinical trials globally, and at least six new therapies expected to be approved in China between 2025 and 2033 [7]. Operational and Strategic Considerations - Yinuo Micro has a small workforce of 86 employees, with plans to expand its team to support clinical and commercial development [7]. - The IPO is seen as a critical move for survival, providing necessary funding for clinical advancements and enhancing the company's credibility in the industry [8].

Core Viewpoint - Immvira Bioscience is advancing its IPO process with a pre-IPO valuation of $485 million, focusing on innovative cancer therapies and leveraging its unique capabilities in CMC and production [1][9]. Company Overview - Immvira Bioscience is the only biotechnology company globally with mature CMC and production capabilities, offering a pipeline that includes oncolytic immunotherapy candidates for solid tumors and innovative engineered exosome therapeutic products [3]. Product Pipeline - The core product, MVR-T3011, is a novel oncolytic immunotherapy based on HSV-1, designed to target a wide range of solid tumors, including bladder cancer and head and neck squamous cell carcinoma [5]. - MVR-T3011 is undergoing a structured development roadmap, with a phased strategy in bladder cancer, including a key Phase II clinical trial for high-risk NMIBC, which is set to complete its first patient dosing in June 2025 [5][6]. - The company has reported promising efficacy and safety data for MVR-T3011 in treating BCG-unresponsive NMIBC, with a 20% objective response rate and a 65% disease control rate observed in prior studies [6]. Regulatory and Development Strategy - The company benefits from a unified "umbrella IND" regulatory framework, allowing multiple clinical evaluations under a single protocol, which enhances development efficiency [7]. - Immvira has established a collaboration with Shanghai Pharmaceuticals for the clinical development and commercialization of MVR-T3011 in Greater China, receiving an upfront payment of 20 million yuan and potential milestone payments up to 1.1 billion yuan [8]. Innovation Platform - The OVPENS platform is central to Immvira's innovative product development, integrating oncolytic immunotherapy and engineered exosome development, covering the entire process from target validation to IND application and GMP-compliant production [8]. - The platform's expansion has also advanced the pipeline of engineered exosome products, which include commercially viable aesthetic products and therapeutic candidates undergoing traditional clinical regulatory pathways [9]. Investment and Valuation - Since its establishment, Immvira has attracted investments from various institutions, with a post-Series C valuation of $485 million [9].

MVR-T3011正在评估作为单药及联合疗法，应用于全谱系膀胱癌、头颈部鳞状细胞癌及其他实体瘤适 应症。 全球溶瘤免疫疗法药物市场预计将从2024年的8710万美元增长至2028年的15.60亿美元(复合年增长率 105.7%)，并于2033年进一步扩大至171.45亿美元。中国溶瘤病毒药物市场预计将从2024年的630万美元 增长至2028年的2.23亿美元(复合年增长率143.9%)，并于2033年进一步攀升至32.71亿美元。 公司专注于发现、开发、生产及商业化新型溶瘤免疫疗法和工程化外泌体疗法，拥有一条包括两款溶瘤 免疫疗法产品和五款工程化外泌体产品在内的管线。核心产品MVR-T3011是一款II期阶段的单纯疱疹病 毒1型(HSV-1)新型溶瘤免疫疗法产品，结合肿瘤溶解作用与抗PD-1抗体及IL-12的表达。 亦诺微医药向港交所主板递交上市申请，联席保荐人为花旗和中金公司（601995）。 ...

据港交所1月14日披露，Immvira Bioscience Inc.(简称：亦诺微医药)向港交所主板递交上市申请，花旗、中金公司（601995）为其联席保荐人。据悉，亦 诺微医药曾于2025年6月25日向港交所主板提交上市申请。 | [编纂]項下的[编纂]數目 : | | [编纂](視乎[编纂]行使與否而定) | | --- | --- | --- | | [编纂]數目 | : | [编纂](可予编纂]) | | [编纂]數目 | : | [编纂](可予[编纂]及視乎[编纂]行使與否而定) | | 最高 编纂] | : | 每股[編纂][編纂]港元,另加1.0%經紀佣金、 | | | | 0.0027％證監會交易徵費、0.00015%會財局交 | | | | 易 徴 費 及 0.00565 % 聯 交 所 交 易 費 ( [ 編 纂]時 須 | | | | 以港元全額繳付,多繳股款可予退還) | | 面值 : | | 每股0.0001美元 | | [编纂] : [编纂] | | | | 聯席保薦人、[編纂] | | | 公司简介 招股书披露，亦诺微医药是一家专注于临床需求导向的生物科技公司，致力于发现、开发 ...

Company Overview - Immvira Bioscience Inc. (亦诺微医药) is a biotechnology company focused on clinical demand-driven solutions, specializing in the discovery, development, production, and commercialization of novel oncolytic immunotherapies and engineered exosome therapies [4] - The company has established a product pipeline that includes two oncolytic immunotherapy products targeting solid tumors and five engineered exosome products with clinical application potential or direct commercialization prospects [4] - The core product, MVR-T3011, is a phase II oncolytic immunotherapy product based on herpes simplex virus type 1 (HSV-1), which combines strong tumor lysis effects with the expression of anti-PD-1 antibodies and IL-12 [4] Financial Information - The company reported revenues of RMB 6.772 million, RMB 3.2 million, and RMB 1.305 million for the fiscal years ending December 31, 2023, December 31, 2024, and the nine months ending September 30, 2025, respectively [6][7] - The company incurred losses of approximately RMB 481.753 million, RMB 523.755 million, and RMB 337.910 million for the same periods [8] - Research and development expenses were significant, amounting to RMB 136.201 million for 2023 and RMB 111.542 million for 2024 [6] Industry Overview - The global oncolytic immunotherapy market is currently in its early stages, characterized by a limited number of commercialized products and low clinical adoption rates [9] - The market is expected to experience rapid expansion, with projections indicating growth from USD 87.1 million in 2024 to USD 1.56 billion by 2028, representing a compound annual growth rate (CAGR) of 105.7% [11] - In China, the oncolytic virus drug market is anticipated to grow from USD 6.3 million in 2024 to USD 223 million by 2028, with a CAGR of 143.9% [14]

Group 1 - The innovative drug sector is experiencing a recovery in market liquidity and policy support, leading to a significant rebound in the IPO market, with 10 biopharmaceutical companies successfully listing on the Hong Kong Stock Exchange in the first half of 2025, raising a total of HKD 17.489 billion [1] - Yinuo Micropharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with a post-financing valuation of USD 485 million (approximately HKD 3.8 billion) [1] - The company's core product is in the II clinical trial phase, focusing on oncolytic immunotherapy, which is considered a relatively "niche" area [1][5] Group 2 - Yinuo Micropharmaceutical has not yet approved any drugs for commercialization and has reported continuous losses, with revenues of approximately RMB 6.772 million, RMB 3.2 million, and RMB 1.287 million for 2023, 2024, and the first quarter of 2025, respectively [2][3] - The company has established external licensing agreements, including a partnership with Shanghai Pharmaceuticals for the MYR-T3011 product, which could yield up to RMB 1.1 billion in milestone payments [2][3] Group 3 - The financial situation of Yinuo Micropharmaceutical is tight, with net liabilities increasing by 41.68% from RMB 1.274 billion to RMB 1.805 billion between 2023 and 2024, and cash and cash equivalents decreasing from RMB 232 million to RMB 112 million [4] - The company plans to conduct II clinical trials for its core product MVR-T3011 targeting non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) starting in late 2026 [8] Group 4 - The oncolytic immunotherapy market is gaining renewed attention, with CG Oncology's candidate therapy achieving a market valuation of around USD 2 billion, indicating strong potential for Yinuo Micropharmaceutical's products [6] - Yinuo Micropharmaceutical's product pipeline includes two clinical-stage oncolytic immunotherapy candidates and three commercially viable engineered exosome products, with MVR-T3011 being the first of its kind to complete Phase I trials via systemic intravenous administration [5][10]

Core Viewpoint - Yinuo Micro Pharmaceuticals has submitted an application for an IPO on the Hong Kong Stock Exchange, focusing on the development of oncolytic immunotherapy and engineered exosome therapies [1][2] Company Overview - Established in 2015, Yinuo Micro Pharmaceuticals specializes in discovering, developing, producing, and commercializing new oncolytic immunotherapies and engineered exosome therapies [1] - The company has a clinical pipeline that includes 2 oncolytic immunotherapy candidates in clinical stages, 2 engineered exosome therapy candidates in preclinical stages, and 3 engineered exosome products ready for commercialization [2] Product Pipeline - The core product, MVR-T3011, is a novel oncolytic immunotherapy based on the HSV-1 virus, targeting bladder cancer and head and neck squamous cell carcinoma [3] - MVR-T3011 is currently in Phase II clinical trials for non-muscle invasive bladder cancer (NMIBC) and Phase I/IIa trials for head and neck squamous cell carcinoma [3][4] Market Landscape - The global market for oncolytic immunotherapy and exosome therapies is still in its early development stages, with limited market size projected at $87.1 million for oncolytic immunotherapy and $1.5 billion for exosome therapies in 2024 [4] - Yinuo Micro Pharmaceuticals is positioned in the first tier of its niche market despite not having any approved therapies for bladder cancer or head and neck squamous cell carcinoma [4] Commercialization Strategy - The company has three engineered exosome products ready for commercialization, including MVR-EX103, which has received INCI certification, allowing it to be used in cosmetic formulations [5][6] - The commercialization strategy focuses on partnerships with international brands and distribution channels, aiming to supply upstream raw materials and potentially launch its own brand in the future [6] Financial Performance - Yinuo Micro Pharmaceuticals has been operating at a loss, with cumulative losses exceeding 2 billion yuan and revenues from external licensing arrangements [9][10] - The company reported revenues of 6.77 million yuan, 3.2 million yuan, and 1.29 million yuan for 2023, 2024, and Q1 2025, respectively, with sales costs significantly exceeding revenues [9] - As of Q1 2025, the company had cash and cash equivalents of 75.61 million yuan, a decrease of 68.93% year-on-year, indicating a need for external financing [10] Investment Considerations - The company has completed seven rounds of financing, raising approximately 1.1 billion yuan, with a post-financing valuation of 4.85 billion USD [10] - The company faces significant challenges in achieving commercialization due to high production costs and complex manufacturing processes for engineered exosomes [7][8]

Core Viewpoint - MVR-T3011 is a potential best-in-class oncolytic immunotherapy for bladder cancer, expected to change the global treatment landscape for this disease [2]. Company Overview - Immvira Bioscience is the only biotechnology company globally with mature CMC and production capabilities, focusing on discovering, developing, producing, and commercializing novel oncolytic immunotherapies and engineered exosome therapies [3]. - The company has submitted its IPO application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [3]. Product Details - MVR-T3011 is a novel oncolytic immunotherapy based on HSV-1, combining potent tumor lysis with the expression of anti-PD-(L)1 antibodies and IL-12, targeting a wide range of bladder cancers and other solid tumor types [4]. - The replication capacity of MVR-T3011 has been enhanced by three logarithmic decades, supporting multiple administration routes, including intratumoral, intravesical, and intravenous delivery, significantly expanding its clinical applicability [4]. - In clinical studies, MVR-T3011 demonstrated excellent efficacy and safety, achieving 85.9%, 77.3%, 77.3%, and 66.3% Kaplan-Meier estimated recurrence-free survival rates at 3, 6, 9, and 12 months, respectively, outperforming Ferring's ADSTILADRIN®, the first and only FDA-approved intravesical gene therapy [4]. Collaboration and Financials - In 2020, Immvira entered into a licensing agreement with Shanghai Pharmaceuticals for MVR-T3011, granting exclusive clinical development and commercialization rights in Greater China [5]. - The company received an initial payment of 20 million yuan and a patent licensing fee of 30 million yuan, with potential milestone payments up to 1.1 billion yuan and a sales revenue share [5]. Innovation Platform - The OVPENS platform is the core engine for the company's innovative product development, integrating oncolytic immunotherapy and engineered exosome development, covering the entire process from target validation to IND application and GMP-compliant production [5]. - OVPENS accelerates vector construction, effective payload optimization, and preclinical evaluation, enabling rapid iteration and efficient advancement across therapies and disease scenarios [5]. Aesthetic Products - The company is developing aesthetic products such as MVR-EX103 for skin-related issues, MVR-EX104 to stimulate comprehensive hair growth, and MVR-EX105 to promote browning of white fat while stimulating muscle growth [7]. - These external exosome products will enter overseas retail markets upon obtaining INCI naming [7]. Valuation - The post-investment valuation of the company in the C+ round is reported to be 485 million USD [8].

Company Overview - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC acting as joint sponsors [1] - The company focuses on clinical demand-driven biotechnology, aiming to discover, develop, produce, and commercialize novel oncolytic immunotherapies and engineered exosome therapies [3] Product Pipeline - The product pipeline includes two clinical-stage oncolytic immunotherapy candidates, two preclinical-stage engineered exosome therapy candidates, and three directly commercializable engineered exosome products [3] - The core product, MVR-T3011, is a novel oncolytic immunotherapy based on HSV-1, targeting a wide range of solid tumors, including bladder cancer and head and neck squamous cell carcinoma [3] - Another candidate, MVR-C5252, is designed for malignant glioma, featuring enhanced safety for intracranial administration and improved immune activation in immunosuppressive tumor environments [4] Market Potential - According to Frost & Sullivan, the global oncolytic immunotherapy market is projected to grow from $8.71 million in 2024 to $1.56 billion by 2028, with a compound annual growth rate (CAGR) of 105.7% [4] Financial Performance - In 2023, 2024, and the first quarter of 2025, the company reported revenues of approximately ¥6.77 million, ¥3.20 million, and ¥1.29 million, respectively [5] - The company incurred losses of approximately ¥481.75 million, ¥523.76 million, and ¥203.80 million for the same periods [5][6]